ESC Professional Premium Access

Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy

Congress Presentation

About the speaker

Doctor Dana Roxana Hiestand

University Hospital Zurich, Zurich (Switzerland)
1 follower

5 more presentations in this session

Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Thumbnail

Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)

Speaker: Doctor M. Tafelmeier (Regensburg, DE)

Thumbnail

Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms N. Felix (Cajazeiras, BR)

Thumbnail

Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry

Speaker: Doctor N. Maurizi (Lausanne, CH)

Thumbnail

The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis

Speaker: Miss S. Lyu (Beijing, CN)

Thumbnail

Access the full session

Contemporary management of hypertrophic cardiomyopathy

Speakers: Doctor D. Hiestand, Doctor P. Garcia-Pavia, Doctor M. Tafelmeier, Ms N. Felix, Doctor N. Maurizi...
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations